New Territory for Medicare

By David Ostrowsky

For the second consecutive July 4^th weekend, a seismic healthcare development has unfolded.

A year ago, the newly-introduced One Big Beautiful Bill Act (OBBA) ushered in a wave of healthcare changes. This year, as Americans were firing up their grills and heading to the beach, it was revealed that effective July 1, millions of Medicare beneficiaries could now access coverage for weight-loss drugs such as Wegovy tablets and injections, Zepbound KwikPens, and Foundayo tablets for $50 a month under a temporary pilot program, officially known as Medicare GLP-1 Bridge. This means, for the first time in the history of Medicare, the program is offering certain enrollees (more on that, soon) coverage for uber-expensive medications that in many cases would be otherwise unaffordable. For Medicare participants at heightened risk for cardiac disease due to diabetes and elevated blood pressure and cholesterol, access to GLP-1 drugs with minimal out-of-pocket expenses is not just a logistical godsend. It’s an acknowledgment that morbid obesity is no different from any other chronic disease that currently warrants publicly-funded health insurance coverage.

But there are, of course, some important stipulations to the Medicare pilot program that warrant strong consideration.

Not All Medicare Enrollees Are Eligible for Medicare GLP-1 Bridge

Truthfully, only select Medicare enrollees will benefit. In order to be eligible, one has to be enrolled in a Part D drug coverage plan and have met very particular health criteria when they began consuming the weight-loss medications. Senior citizens with a body mass index (BMI) of 35 or higher automatically qualify while those whose BMI is between 30 and 35 also need to have one of the following conditions to be eligible: uncontrolled elevated blood pressure; prediabetes; a history of heart attacks and/or stroke; blocked arteries in arms or legs with accompanying symptoms; diastolic heart failure; and chronic kidney disease at Stage 3a or later. For Medicare plan members with a BMI in the 27-30 range, there also needs to be a prediabetic condition; prior heart attack and/or stroke; or blocked arteries in the limbs. Furthermore, if a Medicare enrollee is already consuming a GLP-1 medication for a qualifying condition such as Type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea, they will continue to access the medication via their regular Part D plan. As such, the patient will pay the plan’s price for the GLP-1 medication, which could very well be greater than the $50 copay, meaning that the exact same drug could cost disparate amounts based on why it is prescribed.

Specific Mechanics of the Program

Rather than pursuing the traditional course of action (i.e., going through their Part D plan), Medicare enrollees will need prior authorization to obtain the GLP-1 drugs. In short, the patient’s doctor will send the prescription to a central system; upon approval of the request, the patient will pay the $50 copayment at the pharmacy counter when they pick up their prescription each month. It is important to understand that physicians do not have to be enrolled as Medicare providers to write a prescription or submit a prior authorization request.

How Much Enrollees Can Expect to Pay

Eligible Medicare plan participants are slated to pay $50 for a month’s supply of weight-loss drugs. Notably, this copayment amount does not count towards satisfying the annual deductible or the out-of-pocket maximum. That being said, the $50-a-month price represents a significant price decrease compared to the monthly price range of $149-$699 many senior citizens have grown accustomed to paying. Unfortunately, those enrollees with limited incomes who qualify for Medicare’s Extra Help program will still be subject to the $50 monthly bill.

The Length of Coverage

The Medicare GLP-1 Bridge program is projected to run through the end of 2027, however it is possible that a longer-term program may begin in January 2028. Interestingly, it was initially meant to be a six-month initiative, after which time Medicare Part D insurers would begin offering coverage via another pilot program, Balance, at the onset of ’27. However, there weren’t enough Part D plans that signed up for Balance, which spurred the Centers for Medicare & Medicaid Services (CMS) to lengthen the GLP-1 Bridge program to 18 months.